Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study

被引:139
作者
Arnolds, Sabine [1 ]
Dellweg, Sibylle [1 ]
Clair, Janina [1 ]
Dain, Marie-Paule [2 ]
Nauck, Michael A. [3 ]
Rave, Klaus [1 ]
Kapitza, Christoph [1 ]
机构
[1] Profil Inst Stoffwechselforsch, Neuss, Germany
[2] Sanofi Aventis, Paris, France
[3] Diabet Zentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany
关键词
NPH INSULIN; GLYCEMIC CONTROL; TYPE-2; EFFICACY; SAFETY; MANAGEMENT;
D O I
10.2337/dc09-2191
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - To assess the effect of a 4-week adjunctive therapy of exenatide (EXE) (5-10 mu g bid.) or sitagliptin (SITA) (100 mg once daily) in response to a standardized breakfast meal challenge in 48 men or women with type 2 diabetes receiving insulin glargine (GLAR) + metformin (MET). RESEARCH DESIGN AND METHODS - This was a single-center, randomized, openlabel, active comparator controlled study with a three-arm parallel group design, consisting of: screening, 4- to 8-week run-in period, 4-week treatment period, and follow-up. In all three groups, the GLAR dose was titrated according to an algorithm (fasting blood glucose <= 100 mg/dl). RESULTS - The unadjusted 6-h postprandial blood glucose excursion of both GLAR + MET + EXE and GLAR + MET + SITA was statistically significantly smaller than that of GLAR + MET (606 104 vs. 612 133 vs. 728 132 mg/dl/h; P = 0.0036 and 0.0008). A1C significantly decreased in all three groups (P < 0.0001), with the greatest reduction of -1.9 +/- 0.7 under GLAR + MET + EXE (GLAR + MET + SITA -1.5 +/- 0.7; GLAR + MET -1.2 +/- 0.5%-points; GLAR + MET + EXE vs. GLAR + MET P = 0.0154). The American Diabetes Association A1C target of <7.0% was reached by 80.0, 87.5, and 62.5% of subjects, respectively. GLAR + MET + EXE had the highest number (47) of adverse events, mostly gastrointestinal (56%) with one dropout. GLAR + MET or GLAR + MET + SITA only had 10 and 12 adverse events, respectively, and no dropouts. Hypoglycemia (blood glucose <50 mg/dl) rates were low and comparable among groups. Weight decreased with GLAR + MET + EXE (-0.9 +/- 1.7 kg; P = 0.0396) and increased slightly with GLAR + MET (0.4 +/- 1.5 kg; NS; GLAR + MET + EXE vs. GLAR + MET P = 0.0377). CONCLUSIONS - EKE or SITA added to GLAR + MET further substantially reduced postprandial blood glucose excursions. Longer-term studies in a larger population are warranted to confirm these findings.
引用
收藏
页码:1509 / 1515
页数:7
相关论文
共 25 条
  • [1] Hypoglycaemia in Type 2 diabetes
    Amiel, S. A.
    Dixon, T.
    Mann, R.
    Jameson, K.
    [J]. DIABETIC MEDICINE, 2008, 25 (03) : 245 - 254
  • [2] Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis
    Amori, Renee E.
    Lau, Joseph
    Pittas, Anastassios G.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02): : 194 - 206
  • [3] New treatments in type 2 diabetes: a focus on the incretin-based therapies
    Barnett, Anthony H.
    [J]. CLINICAL ENDOCRINOLOGY, 2009, 70 (03) : 343 - 353
  • [4] Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials
    Bazzano, L. A.
    Lee, L. J.
    Shi, L.
    Reynolds, K.
    Jackson, J. A.
    Fonseca, V.
    [J]. DIABETIC MEDICINE, 2008, 25 (08) : 924 - 932
  • [5] Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
    Gilbert, Matthew P.
    Pratley, Richard E.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2009, 122 (06) : 11 - 24
  • [6] Heine RJ, 2005, ANN INTERN MED, V143, P559, DOI 10.7326/0003-4819-143-8-200510180-00006
  • [7] Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
    Kendall, David M.
    Cuddihy, Robert M.
    Bergenstal, Richard M.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2009, 122 (06) : 37 - 50
  • [8] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
    Kendall, DM
    Riddle, MC
    Rosenstock, J
    Zhuang, DL
    Kim, DD
    Fineman, MS
    Baron, AD
    [J]. DIABETES CARE, 2005, 28 (05) : 1083 - 1091
  • [9] Weight management through lifestyle modification for the prevention and management of type 2 diabetes: Rationale and strategies
    Klein, S
    Sheard, NF
    Pi-Sunyer, X
    Daly, A
    Wylie-Rosett, J
    Kulkarni, K
    Clark, NG
    [J]. DIABETES CARE, 2004, 27 (08) : 2067 - 2073
  • [10] New Drugs for Type 2 Diabetes Mellitus What is their Place in Therapy?
    Krentz, Andrew J.
    Patel, Mayank B.
    Bailey, Clifford J.
    [J]. DRUGS, 2008, 68 (15) : 2131 - 2162